VRNA Stock Overview
A clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Verona Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.25 |
| 52 Week High | US$28.83 |
| 52 Week Low | US$11.39 |
| Beta | 0.44 |
| 11 Month Change | 22.42% |
| 3 Month Change | 109.62% |
| 1 Year Change | 54.13% |
| 33 Year Change | 371.45% |
| 5 Year Change | 519.32% |
| Change since IPO | 101.85% |
Recent News & Updates
Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?
Aug 10
Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
Jun 20Verona Pharma: Key Inflection Point Directly Ahead
May 23Recent updates
Is Verona Pharma (NASDAQ:VRNA) Weighed On By Its Debt Load?
Aug 10Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst
Jun 20Verona Pharma: Key Inflection Point Directly Ahead
May 23Is Verona Pharma (NASDAQ:VRNA) Using Too Much Debt?
Apr 26Verona Pharma: A Few Points From The Bull And Bear Case
Feb 15Is Verona Pharma (NASDAQ:VRNA) A Risky Investment?
Jan 26Verona Pharma: Upcoming PDUFA, Expired Patent, Strong Data
Jan 19Health Check: How Prudently Does Verona Pharma (NASDAQ:VRNA) Use Debt?
Oct 12Does Verona Pharma (NASDAQ:VRNA) Have A Healthy Balance Sheet?
Jun 27Verona Pharma (NASDAQ:VRNA) Has Debt But No Earnings; Should You Worry?
Mar 10Is Verona Pharma (NASDAQ:VRNA) Using Debt In A Risky Way?
Dec 02Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point
Sep 13Verona stock rises as partner Nuance gets China regulator nod to start lung disease drug trials
Aug 19Verona Pharma GAAP EPS of -$0.04 beats by $0.23
Aug 09Verona Pharma: First Inhaled Product Candidate Combining Anti-Inflammatory And Bronchodilator Effects, A Potential Blockbuster
Feb 04Verona Pharma's ensifentrine successful in mid-stage lung disease study; shares up 8%
Feb 02Enrollment completed in Verona Pharma's study of pMDI ensifentrine in COVID-19
Jan 14Verona Pharma EPS beats by $0.15
Oct 29Shareholder Returns
| VRNA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 26.2% | 4.0% | 4.0% |
| 1Y | 54.1% | 16.1% | 24.9% |
Return vs Industry: VRNA exceeded the US Pharmaceuticals industry which returned 15.4% over the past year.
Return vs Market: VRNA exceeded the US Market which returned 21.7% over the past year.
Price Volatility
| VRNA volatility | |
|---|---|
| VRNA Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VRNA's share price has been volatile over the past 3 months.
Volatility Over Time: VRNA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 79 | Dave Zaccardelli | www.veronapharma.com |
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company’s product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler.
Verona Pharma plc Fundamentals Summary
| VRNA fundamental statistics | |
|---|---|
| Market cap | US$2.22b |
| Earnings (TTM) | -US$125.45m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-17.6x
P/E RatioIs VRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRNA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$125.45m |
| Earnings | -US$125.45m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 71.1% |
How did VRNA perform over the long term?
See historical performance and comparison